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Endarterial urokinase in childhood hemolytic uremic syndrome
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The use of thrombolytic drugs in children with hemolytic
uremic syndrome (HUS) is a contentious topic. Although
systemic streptokinase therapy has been reported to reduce
both early mortality Ill and late sequelae. particularly hyperten-
sion [2, 3], carefully controlled trials are lacking. The efficacy of
this relatively dangerous treatment has been difficult to assess
since the mortality rate for HUS in recent years has fallen,
coincident with the early and more skillful application of
intensive care techniques, particularly peritoneal dialysis [4, 5].
We have suggested previously that the local infusion of drugs
into the renal arteries of children with HUS. in conjunction with
serial assessment of renal perfusion by scanning and arterio-
graphic techniques, might allow a safe and controlled evalua-
tion of their efficacy [6]. The present paper describes our
experience with urokinase administered in this way to 8 chil-
dren with severe HUS.
Methods
Clinical data are shown in Table I. Seven children were
referred from other hospitals for management of acute renal
failure; case 5 was admitted directly from home. All had
microangiopathic hemolytic anemia with red cell fragmentation
on blood films and evidence of intravascular coagulation. Each
had developed renal failure following a prodromal illness lasting
up to 14 days, with symptoms referable to either the upper
respiratory or gastrointestinal tract. The 8 children represent
half of those with HUS referred to us between 1974 and 1978.
They were selected for urokinase infusion because of anuria or
oliguria, with evidence of markedly impaired renal perfusion on
dynamic renal scanning. All were treated with hemodialysis or
peritoneal dialysis (begun at the referring hospital in patients 2
and 6), and each received repeated blood transfusions. Other
aspects of our management of acute renal ftdlure in children
have been described in other studies [71. One child in the
present study has been previously reported [6]. The mortality
rate was 12% for children with HUS referred during the period
of the study but not considered sufficiently ill to be treated with
urokinase.
Urokinase administration. With the child sedated, a femo-
ral artery was catheterized percutaneously using the Seldinger
technique, and the catheter (polyurethane or polyethylene)
advanced and manipulated to lie in a renal artery. Following
renal arteriography (bilateral in 7 patients and unilateral in I) a
continuous infusion of urokinase (Urokinase. Leo Laboratories
Ltd, Hayes, Middlesex, UK) was given into one renal artery via
the indwelling catheter. The external diameter of the catheter
varied from 1.2 to 2.2 mm; the ratio of the catheter diameter to
the renal arterial lumen, as measured from the arteriogram.
varied from 0.31 to 0.56. Urokinase was begun within 72 hours
of admission, except in patients 2 and 6 where this interval was
9 and 21 days, respectively. The initial scans in these children
showed only mild impairment of perfusion. Patients 6 and 7
subsequently received a bilateral infusion of urokinase after
intervals of 21 and 0 days, respectively. The dosage and
duration of the infusions are shown in Table I. In addition to
urokinase, all children received a low dose of heparin. 100 to
250 U/kg of body wt per 24 hours, subcutaneously in 5 cises
and by the endarterial infusion in patients I. 2. and 7. Three
children also received oral dipyridamole. 10 mg/kg of body WI
per 24 hours. These additional therapies were continued until
the blood film no longer showed microangiopathy.
Early assessment. Renal blood flow was assessed in all
patients by imaging with a gamma camera after the iv. bolos
injection of 99m technetium-labeled diethylenetriamine penta-
cetic acid (DTPA) [81. Images were recorded on Polaroid or X-
ray film during the first 30 sec after injection and at 2. 5. 10. 15,
20, and 30 mm. These studies were performed before, during.
and following the urokinase infusion. Each individual study was
interpreted by one of us independently of clinical information.
Renal perfusion was graded as improved, unaltered, or deterio-
rated.
Renal arteriography was repeated bilaterally in 4 children and
in I child on the infused side only. In 3 patients urokinase was
continued after the second arteriogram: in one of these further
arteriography was obtained at the end of the infusion. Renal
vessel caliber and filling of peripheral vessels were assessed in
each child retrospectively by one ofus independently of cliniical
information. Changes were graded as improved, unaltered, or
deteriorated.
Late assessment. Among the children observed, 3 died. Of
the 5 surviving children, 4 were seen I to 5 years after initial
presentation. Evaluation included clinical examination, mea-
surement of blood pressure, and urinalysis. Glomerular filira-
tion rate was estimated from the clearance of intravenously
administered 5tCr-EDTA [91, and divided renal function was
measured 3 hours after an i.v. injection of 99m Technetium-
labeled dimercaptosuccinic acid (DMSA) by static scanning
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3 4.0 5.5
4 4.2 8.7
5 5.8 4.6
6 6.7 6.7
7 9.9 5.0
3 Bilateral severe
impairment,
worse on infused
side
4 Bilateral equally
severe
impairment
5 Bilateral severe
impairment,
worse on infused
side
6' Bilateral moder-
ate impairment.
worse on non-in-
fused side
7 Bilateral equally
severe
impairment
8 Bilateral severe
impairment,
worse on infused
side
FDI
titerh
(normal
< 1/5)
1/40
1/5
87 727
136 1415
120 1600
49 490
37 596
65
Days from Guy's
admission to
Onset of uro- Urokinase
kinase infusion, dosage,(no. of days at Ploug units
referring hospital) per24 hr
1(13) 25,000
9 (4) 50,000w
75,000
100 ,000
75,0O0
100,000
100,000
2 (5)
<1(1)
<I (-)
21(30)
Table 2. Early assessment of effects of urokinase on renal perfusion
Following urokinase
Bilateral equal im-
provement 3 weeks
later
Bilateral equal im-
provement 7 days
later
— Bilateral equal im-
provement 12 days lat-
er, infused side re-
maining worse
Bilateral equal im-
provement 5 days
later
Bilateral equal im-
provement 2 days lat-
er, infused side re-
maining worse
No change
Bilateral equal im-
provement I day later
Equal bilateral
deterioration
Initial
Equally poor perfusion
bilaterally
Equally poor perfusion
bilaterally
Poor perfusion, infused
side worse
Poor perfusion, only
infused side studied
Poor perfusion, infused
side worse
Poor perfusion, nonin-
fused side worse
3(2)
t)eterioration on
infused side, no
change on nonin-
fused side
Duration of
urokinase
infusion,
hours
120
96
72
48
96
72
48
168
l00.000' 72
48
168
using a gamma camera interfaced to a dedicated minicomputer
[101, The kidneys of 2 of the 3 children who died were examined
post-mortem; in the third child permission for post-mortem was
refused. The kidneys of the fifth surviving child were examined
following bilateral nephrectomy prior to renal transplantation.
Detailed histological comparisons between the treated and
untreated kidneys were not available.
Results
In all children the initial DTPA scans showed evidence of
impaired renal perfusion, with decrease or delay in the arterial
phase following tracer injection. The renal arteriographic ap-
pearances were of diminished arterial caliber and impaired
filling of peripheral vessels. The changes following urokinase
infusion are summarized in Table 2. In only one child, patient 8,
Table 1. Clinical data on referral and details of urokinase infusion
Patient Age Hemoglobin Platelets
no. years gid! x I0'/mm'
1 0.2 8.4 34
2 1.7 4.2 167
Reptilase
time
(control Serum urea
12 to 13 see) ,nrnoles/liter
19 22
22 86
Serum
creatini ne
imoles/liter
303
445
10 1/20 32
95 — 18
97 — 16
97 1/5 13
14 1/40 23
208 13.4 8.5 140 1/10
HAll cases showed red cell fragmentation on blood film.
5FDP = fibrin degradation products.
cDosage increased after first 96 hours of infusion.
4Also received oral dipyridamole.
Unilateral (a) followed by bilateral (6) infusion.
Patient
585 2 (2)
DTPA scintigraphy
no. Initial [)uring urokinase
I No perfusion or No change
function on ei-
ther side
2 Bilateral equally No change
severe
impairment
100.000
Following urokinase
Further deterioration
on infused side
Renal arteriography
l)uring urokinase
No change
No change
No change during
unilateral infusion;
equal improvement
during bilateral
infusion
No change during
unilateral or bilater-
al infusion
Transient bilateral
improvement, espe-
cially on infused
side
— Deterioration, only
infused side studied
— Improvement on
noninfused side only
Equally poor perfusion Bilateral equal
bilaterally improvementh
Equally poor perfusion Bilateral equal
bilaterally improvement
a Unilateral followed by bilateral urokinase infusion; arteriography performed after unilateral infusion.
h Catheter noted to have slipped Out of renal artery into descending aorta.
Hemolytic uremic syndrome 725
Urinary
protein
Patient Followup (> 200 trig per
no. years 24 hrs) Hypertension
3 2.5
4 3.3 +
7 4.9
8 1.2 +
43
53
56/44
40
Difference of greater than 10% between kidneys is considered significant.
bReceived unilateral followed by bilateral urokinase infusiom 56% of function contributed by kidney receiving least urokinase.
did serial DTPA scans suggest greater improvement in blood
flow to the infused kidney compared to the noninfused kidney.
However, this difference was not maintained subsequently and
was not confirmed by repeat arteriography, which showed
equal improvement in the vascular pattern bilaterally.
Serial estimations of thrombin and reptilase times, and fibrin
degradation products, did not show any changes during uroki-
nase infusion to suggest a systemic fibrinolytic effect on the
coagulation system. No significant change in hemoglobin or
platelet count occurred (Student's t test). No immediate mor-
bidity associated with the use of the endarterial catheterwas
noted.
Followup data in 4 of the survivors are shown in Table 3. All
survivors except one had recovered normal renal function.
There was no evidence of greater recovery of function in the
treated compared to the untreated kidney. In patients 3 and 8
the divided function from the DMSA scan showed a greater
contribution to overall renal function from the non-infused
kidney. However, in both of these children DTPA scans at
presentation had suggested that the non-infused kidney had
been less severely affected (Table 2). In patient 7, who had
received a unilateral followed by a bilateral infusion, patchy
uptake of DMSA suggested bilateral renal cortical scarring. In
patient 8 recovery of renal function was sufficient to allow
discontinuation of maintenance hemodialysis 13 months after
presentation, at which time the GFR was 5 mI/mm per 1.73 m2.
One year later it had risen further to 23 mI/mm per 1.73 m2, but
there was persistent hypertension.
One child, patient 2, died 9 months after presentation. She
was in chronic renal failure, severely hypertensive, with a left
hemiplegia. A CAT scan showed cerebral infarction. During the
postmortem examination, the infused kidney weighed 17 g the
noninfused kidney, 18 g.
Figure 1 shows the postmortem appearance of the kidneys of
patient 1, who died of progressive renal failure and neurological
complications 3 months after presentation. The infused kidney
was considerably smaller than the noninfused kidney (weights
not available). The ratio of the diameter of the endarterial
catheter to the renal arterial lumen in this case was 0.56.
Patient 5 died 2 months after presentation, also from renal
failure and neurological damage. Permission for a postmortem
examination was refused.
Patient 6, who had received a unilateral followed by bilateral
urokinase infusion, underwent bilateral nephrectomy because
of hypertension, prior to renal transplantation 10 months after
initial presentation. The kidney originally infused weighed 25 g
and the contralateral kidney, 27 g.
Discussion
Controlled trials of streptokinase in childhood HUS have
been widely advocated but difficult to design [ill. and the
significant incidence of serious bleeding during systemic Ireat-
ment [2, 111 has made this therapy unacceptable to some [12].
The present study was performed in an attempt to overcome
these problems by giving the non-antigenic thrombolytic agent
urokinase by a low dosed infusion directly into one renal artery.
thereby avoiding systemic effects and enabling the non-infused
kidney to serve as a control. Renal scanning allowed assess-
ment of both the immediate and long-term effects of treatment.
The encouraging therapeutic potential for locally infused
urokinase suggested by our previous case report 161 was not
confirmed by the present study, which failed to demonstrate
any beneficial effects. In one patient (8) DTPA scan did suggest
initially greater improvement in renal blood flow on the treated
side; however, this difference was not maintained during further
urokinase administration, and it was not confirmed by repeated
renal arteriography. In addition, assessment one year later
showed that the infused kidney contributed less to overall renal
function than the noninfused side. The greater improvement in
renal blood flow on the untreated side, observed also in patient
3, might have reflected the greater severity of involvement of
the infused kidney at the time of presentation (the initial DTPA
scans suggested such a disparity in these two cases). However.
it is also possible that the presence of an indwelling cat deter
may have impaired renal blood flow and subsequent recovery of
function, although DTPA scans did not show any diminution of
perfusion following placement of the catheter. However, the
possibility that the presence of the catheter may have impaired
renal blood flow is suggested also by the shrunken appearance
of the treated kidney during the postmortem examination in
patient I (Fig. I), in which the kidneys had appeared equally
affected at presentation, and the catheter had been largcst in
relation to the renal arterial lumen.
Optimum dosage of urokinase for endarterial infusion in [-IUS
is not known. We used a dose similar to that given by others to
patients with HUS [131 and post-partum renal failure [14], and
one which in the case of streptokinase has been found to
successfully lyse intra-arterial thrombi in vivo [151. The possi-
bility that a significant systemic fibrinolytic effect, and there-
fore an effect on the contralateral kidney, might have occurred
in the present study is unlikely in view of the stability of the
coagulation tests during the infusion. Although a minor effect
cannot be excluded, the dosage used was less than one tenth of
that recommended for a systemic fibrinolytic effect in the
treatment of pulmonary embolism [16].
Table 3. Late assessment in 4 survivors
G FR
jul/minI! .73 m2
94
107
102
Divided renal functicn
on DMSA scintigraphy
U rokinase-
treated
kidney
4-
U ntreated
kidney
7'
.56
46
59
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Fig. 1. Post marie/n appear-
ance qf the kidneys in patient
1. The smaller. contracted,
scarred kidney on the right is
the one that received uroki-
nase.
A factor that may compromise the success of any treatment
in HUS is the delay between the onset of the disease and the
initiation of treatment. In some children in the present study
this delay was considerable and was increased by time spent at
the referring hospital. However, even in those children who
received urokinase early in their illness (less than 48 hours after
presentation in patients 4 and 5) no benefit could be demonstrat-
ed.
Patients were selected for treatment with urokinase on the
basis of severe disease and the possibility of' impending renal
cortical necrosis, suggested both clinically and by evidence
from DTPA scan of severely impaired renal perfusion. The
recovery of normal renal function without hypertension in 3
children underlines the difficulty in selecting at presentation
those children most likely to benefit from potentially dangerous
treatment. Also noteworthy is the delayed recovery of renal
function in patient 8, who was able to discontinue maintenance
hemodialysis 13 months after initial presentation.
The results of the present study failed to show that locally
infused urokinase is of benefit in childhood I-ILlS. Moreover,
such treatment may he harmful. The study also failed to provide
any corroborative evidence for the likelihood of a beneficial
effect from systemic thrombolytic treatment. Our results do not
enable us to comment on the possibility that systemic treatment
may prevent the development of hypertension in surviving
children 12, 3j.
Mortality in the present small series of severely affected
children was high. However, others have shown that with
attention to supportive treatnieni. particularly (he early institu-
tion of peritoneal dialysis, the mortality from childhood HUS
can he reduced to 10% or less, even in severely affected
children 151. Finally, we agree with the view 1121 that thromho-
lytic agents are not indicated in the management of this disease
except where controlled trials arc being undertaken in severe
cases and where the hematological affects are being monitored
closely.
Siuninary. Urokinase was given by unilateral infusion for 48—
168 hours into the renal arteries of 8 children (0.2 to 13.0 years)
with acute renal failure and impaired renal perfusion clue to
hemolytic uremic syndrome (HUS). Two children subsequently
received a bilateral infusion. Immediate changes in renal perfu-
sion were assessed by serial dynamic renal scanning in all
patients and by repeat renal arteriography in 5. No improve-
ment clearly attributable to urokinase was observed. In 4
surviving children assessment of divided renal function by
static renal scanning I to 5 years after presentation showed no
evidence of benefit from urokinase. Exaniination of the kidneys
of 2 of the 3 children who died. and one who underwent bilateral
ncphrectomy prior to renal transplantation, showed no preser-
vation of renal mass attributable to urokinase: in one of these
children the infused kidney was considerably smaller than the
untreated kidney. it is concluded that local infusion of uroki-
nase had no beneficial effect on the course of HUS in these
children.
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